SCHEMBL5065463

SCHEMBL5065463

Cc1nc(Nc2ccc(C)c(C)c2)c2nc(C)sc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.45
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
RAF1 P04049 1/20 0.45
MAPK1 P28482 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TRPV1 Q8NER1 1/20 0.45
DHODH Q02127 1/20 0.40
KDR P35968 1/20 0.40
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HTT P42858 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 3/20 0.38
FGFR1 P11362 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061315 0.84 MAPT (0.44) MAPTALDH1A1SMN1; SMN2RAF1MAPK1
SCHEMBL5068960 0.82 TRPV1 (0.40) MAPTALDH1A1SMN1; SMN2TRPV1KDR
SCHEMBL5064175 0.81 KDR (0.47) MAPTALDH1A1SMN1; SMN2TRPV1KDR
SCHEMBL5068853 0.81 KDR (0.47) MAPTALDH1A1SMN1; SMN2TRPV1DHODH
SCHEMBL5068900 0.81 ADORA3 (0.57) MAPTALDH1A1MAPK1TRPV1KDR
SCHEMBL5068972 0.77 TRPV1 (0.53) MAPTSMN1; SMN2MAPK1TRPV1HSD17B10
SCHEMBL5064108 0.77 TRPV1 (0.41) MAPTTRPV1KDRLMNAFGFR1
SCHEMBL5109235 0.73 SRC (0.41) MAPTALDH1A1SMN1; SMN2RAF1MAPK1
SCHEMBL16604696 0.71 ADORA3 (0.35) GAAADORA3ADORA2AADORA2BADORA1
SCHEMBL5116795 0.71 TRPV1 (0.59) TRPV1DHODHKDRADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US claimed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP claimed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 MAPT 4180/4885ALDH1A1 1911/4885SMN1; SMN2 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.